Headache News and Research RSS Feed - Headache News and Research

Pharmacist suggests education as foremost strategy to control opioid abuse

Pharmacist suggests education as foremost strategy to control opioid abuse

Technologies that make it harder for people to abuse opioids - like doctoring pills so that they produce unpleasant side effects if broken, crushed or injected -- likely will have limited effectiveness in stemming the global epidemic of opioid abuse, according to Adam Kaye, a professor of pharmacy at University of the Pacific. [More]
First buprenorphine implant for opioid dependence treatment gets FDA approval

First buprenorphine implant for opioid dependence treatment gets FDA approval

The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program. [More]
Exposing headache sufferers to pure-wavelength green light can lessen severity of migraines

Exposing headache sufferers to pure-wavelength green light can lessen severity of migraines

Most migraine and post-traumatic headache sufferers find their headaches get worse in light, leading them to quit their most fundamental daily tasks and seek the comfort of darkness. [More]
Magic mushroom compound may offer potential new way for antidepressant research

Magic mushroom compound may offer potential new way for antidepressant research

Psilocybin – a hallucinogenic compound derived from magic mushrooms – may offer a possible new avenue for antidepressant research, according to a new study published in The Lancet Psychiatry today. [More]
WHO/PAHO statement on Zika virus and the 2016 Rio Olympic and Paralympic Games

WHO/PAHO statement on Zika virus and the 2016 Rio Olympic and Paralympic Games

The World Health Organization (WHO) and the Pan American Health Organization (PAHO) recognize that athletes and visitors are seeking more information on the risks of Zika and ways to prevent infection while attending the 2016 Rio Olympic and Paralympic Games (5 August to 18 September 2016). [More]

GammaCore both effective and cost effective for the treatment of cluster headache

A paper in the Journal of Headache and Pain reports that non-invasive stimulation of the vagus nerve (nVNS) is a cost effective therapy for cluster headache. These findings were based on reductions in medication use and improvements in quality of life. The publication also notes that further economic benefits would have been found had reduced visits to clinics been taken into account. [More]
Neos announces U.S. launch of Adzenys XR-ODT for ADHD

Neos announces U.S. launch of Adzenys XR-ODT for ADHD

Neos Therapeutics, Inc., a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR) product candidates for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that Adzenys XR-ODT™ is in distribution channels and is now available to prescribe for patients with ADHD in the United States. [More]
Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

New analyses presented at the American Thoracic Society’s 2016 annual conference (ATS 2016) further add to the efficacy and safety profile of OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF). [More]
Important signs, symptoms of stroke that everyone should know

Important signs, symptoms of stroke that everyone should know

Almost 795,000 Americans suffer from stroke each year, 130,000 which are fatal, making stroke the fifth leading cause of death in the United States. [More]
BetterYou Magnesium Oil spray relieves migraine pain in 43-year old mum

BetterYou Magnesium Oil spray relieves migraine pain in 43-year old mum

A 43-year old mum of one from Bristol, who suffered from frequent painful migraines for almost a decade has found relief thanks to BetterYou™ Magnesium Oil spray. [More]
UCLA neurologist highlights steps that can help Americans reduce stroke risk

UCLA neurologist highlights steps that can help Americans reduce stroke risk

Getting more exercise, giving up cigarettes and monitoring cholesterol and blood pressure are a few steps Americans can take to reduce their risk of stroke, says Doojin Kim, MD, a neurologist at UCLA Medical Center, Santa Monica who often treats patients who have suffered a stroke, the No. 4 cause of death and the No. 1 cause of adult disability in the U.S. [More]
Experimental drug ozanimod moderately effective in treatment of ulcerative colitis

Experimental drug ozanimod moderately effective in treatment of ulcerative colitis

Researchers at University of California San Diego School of Medicine have shown that ozanimod (RPC1063), a novel drug molecule, is moderately effective in the treatment of ulcerative colitis. Results of the Phase II clinical trial will appear in the May 5 issue of the New England Journal of Medicine. [More]
Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress. [More]
Study evaluates effects of corticosteroids along with anti-tuberculosis drugs in tuberculous meningitis

Study evaluates effects of corticosteroids along with anti-tuberculosis drugs in tuberculous meningitis

The Cochrane Infectious Diseases Group have carried out a review update to evaluate the effects of corticosteroids being used alongside anti-tuberculosis medication to treat people suffering from tuberculous meningitis. [More]

Modified surgical technique may be effective treatment option for chronic temporal headache

A modified surgical technique may provide a simpler approach to the surgical treatment for one type of chronic headache, according to an "Ideas and Innovations" paper in the May issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS). [More]
First generic version of Crestor gets FDA approval

First generic version of Crestor gets FDA approval

The U.S. Food and Drug Administration today approved the first generic version of Crestor (rosuvastatin calcium) tablets. [More]
More neurological resources needed to manage Zika virus infections

More neurological resources needed to manage Zika virus infections

WFN Zika-Info-Service: World Federation of Neurology establishes Work Group on Zika virus to support international efforts - Lack of neurological resources in countries most concerned by the virus. [More]
Study highlights significant burden of migraine on family activities

Study highlights significant burden of migraine on family activities

The debilitating pain and disability of migraine also attacks the emotional, social and financial fabric of a family, according to a new study conducted by researchers at Montefiore Headache Center, Albert Einstein College of Medicine, affiliated with the Uniformed Services University of the Health Sciences, Vedanta Research, the Mayo Clinic and Allergan plc. The findings were published today in Volume 91, Issue 5 of Mayo Clinic Proceedings. [More]
Updated guidance on botulinum toxin formulations for four indications

Updated guidance on botulinum toxin formulations for four indications

The American Academy of Neurology has issued an update to its 2008 guidelines on the use of botulinum toxin for the treatment of spasticity, cervical dystonia, blepharospasm and migraine headache. [More]
Bupropion, varenicline drugs do not increase risk of serious neuropsychiatric adverse events

Bupropion, varenicline drugs do not increase risk of serious neuropsychiatric adverse events

Compared to the nicotine patch and a placebo, the smoking cessation aids varenicline (marketed as Chantix in the U.S.) and bupropion (Zyban) do not show a significant increase in neuropsychiatric adverse events, reports an international team of researchers in a study published online April 22 in the journal The Lancet. [More]
Advertisement
Advertisement